Christensen Amy, McGill Cassandra J, Qian Wenjie, Pike Christian J
Davis School of Gerontology, University of Southern California, Los Angeles, CA, United States.
Front Aging Neurosci. 2024 Sep 13;16:1415072. doi: 10.3389/fnagi.2024.1415072. eCollection 2024.
The main genetic risk factor for Alzheimer's disease (AD) is the apolipoprotein E ε4 allele (). AD risk associated with disproportionately affects women. Furthermore, human and rodent studies indicate that the cognitive deficits associated with are greater in females. One modifiable AD risk factor is obesity during middle age. Given that approximately two-thirds of US adults are overweight, it is important to understand how obesity affects AD risk, how it interacts with , and the extent to which its detrimental effects can be mitigated with therapeutics. One intervention study for women is estrogen-based hormone therapy, which can exert numerous health benefits when administered in early middle age. No experimental studies have examined the interactions among , obesity, and hormone therapy in aging females. To begin to explore these issues, we considered how obesity outcomes are affected by treatment with estradiol at the onset of middle age in female mice with human and . Furthermore, to explore how gene dosage affects outcomes, we compared mice homozygous for (3/3) and homozygous (4/4) or hemizygous (3/4) for . Mice were examined over a 4-month period that spans the transition into reproductive senescence, a normal age-related change that models many aspects of human perimenopause. Beginning at 5 months of age, mice were maintained on a control diet (10% fat) or high-fat diet (HFD; 60% fat). After 8 weeks, by which time obesity was present in all HFD groups, mice were implanted with an estradiol or vehicle capsule that was maintained for the final 8 weeks. Animals were assessed on a range of metabolic and neural measures. Overall, was associated with poorer metabolic function and cognitive performance. However, an obesogenic diet induced relatively greater impairments in metabolic function and cognitive performance in mice. Estradiol treatment improved metabolic and cognitive outcomes across all HFD groups, with generally exhibiting the greatest benefit. mice were intermediate to the homozygous genotypes on many measures but also exhibited unique profiles. Together, these findings highlight the importance of the genotype as a modulator of the risks associated with obesity and the beneficial outcomes of estradiol.
阿尔茨海默病(AD)的主要遗传风险因素是载脂蛋白Eε4等位基因()。与该等位基因相关的AD风险对女性的影响尤为显著。此外,人类和啮齿动物研究表明,与之相关的认知缺陷在女性中更为严重。一个可改变的AD风险因素是中年时期的肥胖。鉴于约三分之二的美国成年人超重,了解肥胖如何影响AD风险、它如何与该等位基因相互作用以及其有害影响可通过治疗减轻的程度非常重要。一项针对女性的干预研究是基于雌激素的激素疗法,在中年早期进行该疗法可带来诸多健康益处。尚无实验研究探讨该等位基因、肥胖和激素疗法在衰老雌性动物中的相互作用。为了开始探索这些问题,我们研究了在具有人类该等位基因的雌性小鼠中年开始时用雌二醇治疗如何影响肥胖相关结果,并比较了该等位基因纯合子(3/3)和纯合子(4/4)或半合子(3/4)小鼠。在跨越向生殖衰老过渡的4个月期间对小鼠进行检查(生殖衰老是一种与年龄相关的正常变化过程,模拟了人类围绝经期的许多方面)。从5月龄开始,将小鼠分别维持在对照饮食(10%脂肪)或高脂饮食(HFD;60%脂肪)中。8周后,此时所有HFD组均出现肥胖,给小鼠植入雌二醇或对照胶囊,并持续8周。对动物进行一系列代谢和神经指标评估。总体而言,该等位基因与较差的代谢功能和认知表现相关。然而,致肥胖饮食在该等位基因小鼠中诱导出相对更严重的代谢功能和认知表现损害。雌二醇治疗改善了所有HFD组的代谢和认知结果,其中该等位基因纯合子小鼠通常受益最大。在许多指标上,该等位基因杂合子小鼠表现介于纯合子基因型之间,但也呈现出独特的特征。总之,这些发现凸显了该等位基因作为肥胖相关风险及雌二醇有益结果调节因子的重要性。